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Abstract
Objective—To assess the relationship between abnormally increased P-wave terminal force in 
lead V1 (PTFV1), an electrocardiographic (ECG) marker of left atrial abnormality, and incident 
ischemic stroke subtypes. We hypothesized that associations would be stronger with non-lacunar 
stroke, since we expected left atrial abnormality to reflect the risk of thromboembolism rather than 
in-situ cerebral small-vessel occlusion.
Methods—Our cohort comprised 14,542 participants 45-64 years of age prospectively enrolled 
in the Atherosclerosis Risk in Communities (ARIC) study and free of clinically apparent atrial 
fibrillation (AF) at baseline. Left atrial abnormality was defined as PTFV1 >4,000 μV*ms. 
Outcomes were adjudicated ischemic stroke, non-lacunar (including cardioembolic) ischemic 
stroke, and lacunar stroke.
Results—During a median follow-up period of 22 years (interquartile range, 19-23 years), 904 
participants (6.2%) experienced a definite or probable ischemic stroke. A higher incidence of 
stroke occurred in those with baseline left atrial abnormality (incidence rate per 1,000 person-
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years, 6.3; 95% CI, 5.4-7.4) than in those without (incidence rate per 1,000 person-years, 2.9; 95% 
CI, 2.7-3.1; P < 0.001). In Cox regression models adjusted for potential confounders and incident 
AF, left atrial abnormality was associated with incident ischemic stroke (HR, 1.33; 95% CI, 
1.11-1.59). This association was limited to non-lacunar stroke (HR, 1.49; 95% CI, 1.07-2.07) as 
opposed to lacunar stroke (HR, 0.89; 95% CI, 0.57-1.40).
Interpretation—We found an association between ECG-defined left atrial abnormality and 
subsequent non-lacunar ischemic stroke. Our findings suggest that an underlying atrial 
cardiopathy may cause left atrial thromboembolism in the absence of recognized AF.
Atrial fibrillation (AF) is associated with a 3- to 5-fold heightened risk of ischemic stroke.1 
This risk has long been ascribed to stasis of blood and thrombus formation resulting from 
the loss of an organized atrial rhythm.2 However, the heart-rhythm disturbance that 
characterizes AF is associated with other atrial derangements such as endothelial 
dysfunction,3 fibrosis,4 impaired myocyte function,5 and chamber dilatation.6 Recent 
evidence suggests that these other atrial derangements play an independent role in causing 
stroke, and that the dysrhythmia that defines AF is not always necessary for left atrial 
thrombus formation and embolization to occur.7-13 In a prospective study of patients with 
pacemakers or defibrillators, 31% of those with both AF and stroke had no evidence of AF 
during 8 months of heart-rhythm monitoring prior to their stroke, and manifested the 
dysrhythmia for the first time after the stroke.13 Therefore, the heart-rhythm disturbance 
may not fully account for the association between AF and stroke.
We recently found that abnormally increased P-wave terminal force in lead V1 (PTFV1)—
the most commonly used electrocardiographic (ECG) marker of left atrial abnormality14—is 
associated with ischemic stroke11 and radiographic evidence of vascular brain injury12 in 
patients with apparent normal sinus rhythm. These findings were unchanged regardless of 
adjustment for incident diagnoses of AF during follow-up, suggesting that ECG-defined left 
atrial abnormality reflects atrial dysfunction that can cause stroke even in the absence of AF.
This hypothesis would be further strengthened by demonstrating associations between left 
atrial abnormality and specific ischemic stroke subtypes. We hypothesize that ECG-defined 
left atrial abnormality is a marker of an atrial cardiopathy that may result in thrombus 
formation and embolization to the brain, rather than a marker of generally increased vascular 
risk from systemic factors such as hypertension and atherosclerosis. Since cardiac embolism 
typically results in large or cortical strokes rather than small subcortical strokes (lacunar 
strokes),15 we expect a stronger association between left atrial abnormality and non-lacunar 
stroke than with lacunar stroke. Such a specific association would be consistent with our 
hypothesis that left atrial abnormality can cause thromboembolism in the absence of AF. We 
previously found an association between left atrial abnormality and incident ischemic stroke 
in the Atherosclerosis Risk in Communities (ARIC) cohort,16 but this analysis did not adjust 
for AF and did not compare ischemic stroke subtypes. Therefore, we examined the 
hypothesis that ECG-defined left atrial abnormality is more strongly associated with non-
lacunar rather than lacunar stroke in this cohort, and adjusted for diagnosis of AF during 
follow-up.
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Study Design and Population
The Atherosclerosis Risk in Communities (ARIC) study prospectively enrolled 15,792 
community-dwelling men and women 45-64 years of age. Four field centers across the 
country (Washington County, MD; Forsyth County, NC; Jackson, MS; Minneapolis 
suburbs, MN) recruited participants in 1987-1989. Participants returned for three follow-up 
examinations during the follow-up time period (1990-1992, 1993-1995, and 1996-1998), 
and continue to be followed via annual telephone calls to ascertain study end points. 
Endpoints are further ascertained from examination of lists of hospital discharges that 
include any cardiovascular diagnoses from hospitals in the study communities. For this 
analysis, we excluded participants with hemorrhagic stroke, AF at baseline, missing or 
unreliable baseline ECG data, or missing data on other baseline covariates.
Measurements
Digital 12-lead ECGs were obtained at baseline and at the three follow-up examinations 
using MAC PC ECG machines (Marquette Electronics, Milwaukee, WI). All ECGs were 
inspected for technical errors and adequate quality at the EPICORE Center at the University 
of Alberta (Edmonton, Alberta, Canada) during the initial phases of the study and at the 
EPICARE Center at Wake Forest University (Winston-Salem, North Carolina, USA) during 
later phases. Our primary predictor variable was left atrial abnormality, defined by the 
commonly used ECG criterion of PTFV1 >4,000 μV*ms.14, 17-20 PTFV1 was defined as the 
duration (ms) times the absolute value of the depth (μV) of the downward deflection 
(terminal portion) of the median P-wave in lead V1 (Figure 1). In our study, the waveforms 
required to calculate PTFV1 (P’dur and P’amp in V1) were automatically measured from the 
baseline ECG using the GE Marquette 12-SL program (GE Marquette, Milwaukee, WI). 
These digital waveform measurements have a time resolution of approximately 2 ms and an 
amplitude resolution of approximately 5 μV.21 To validate the accuracy of the automated 
ECG measurements used to derive PTFV1, the waveforms required to calculate PTFV1 
(P’dur and P’amp in V1) were manually measured from ECGs in a subset of 150 participants 
by a single investigator (H.K.) blinded to the automated measurements, and the calculated 
PTFV1 values were then compared. This analysis demonstrated an excellent inter-rater 
correlation coefficient (0.82; 95% CI, 0.76-0.87). Furthermore, the classification of PTFV1 
as normal (≤4,000 μV*ms) versus abnormal (>4,000 μV*ms) based on automated 
measurements had a 94% agreement rate when compared with the manual scoring of these 
150 ECGs. These findings are consistent with prior work demonstrating that the 
ascertainment of left atrial abnormality based on automated measurements by the 12-SL 
program has a positive predictive value of 100% and a negative predictive value of 99.8% 
when compared to the review of the ECG by two cardiologists.22
Our outcomes were definite or probable ischemic stroke, lacunar ischemic stroke, and non-
lacunar ischemic stroke. Details of methods used to ascertain and classify strokes in ARIC 
have been previously published.23 Cases of possible stroke were first identified during 
annual telephone calls or review of hospital discharge diagnoses. Medical records pertaining 
to these possible stroke events were then reviewed and abstracted by a single trained nurse at 
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a central site (University of Minnesota). Based on these abstracted records, the occurrence 
and type of stroke was classified by a software algorithm that applied validated criteria from 
the National Survey of Stroke by the National Institute of Neurological Disorders and 
Stroke.24 This software algorithm classified strokes as hemorrhagic, cardioembolic, or 
thrombotic. A physician investigator independently reviewed the medical record and 
separately determined the occurrence of stroke and whether it was hemorrhagic, 
cardioembolic, or thrombotic. Cases of disagreement between the software program and 
physician reviewer were adjudicated by a second physician. In cases of a definite thrombotic 
stroke, the physician reviewer further adjudicated these as lacunar or non-lacunar. Diagnoses 
of lacunar stroke were based predominantly on characteristic imaging findings while 
accounting for the available data on symptomatology. A definite lacunar infarction required 
anatomic locations typical of lacunar infarctions (basal ganglia, brain stem, thalamus, 
internal capsule, or cerebral white matter), and an estimated infarct size of ≤2 cm or an 
infarct of unstated size. All other definite thrombotic strokes, as well as all definite 
cardioembolic strokes, were classified as non-lacunar. All stroke adjudications were 
performed while blinded to PTFV1 classifications.
Since AF may explain the association between ECG-defined left atrial abnormality and 
stroke,16 we examined this association after adjusting for incident AF. Cases of AF were 
identified from study visit ECGs and by review of hospital discharge diagnoses.25 At each 
study exam, a standard supine 12-lead resting ECG was recorded with the MAC PC ECG 
software used for automatic coding. A cardiologist visually confirmed all AF cases 
automatically detected from the study ECG. Information on hospitalizations during follow-
up was obtained from annual follow-up calls and surveillance of local hospitals, with 
hospital discharge diagnosis codes collected by trained abstractors. AF during follow-up was 
defined by International Classification of Diseases, 9th Revision codes 427.31 or 427.32. AF 
cases detected in the same hospitalization as open cardiac surgery were not included since 
these are usually considered transient.26 Hospital diagnosis codes for AF ascertainment have 
been shown to have good positive predictive value.27
We used data from the baseline examination to adjust for the following potential 
confounders: age, sex, race, body mass index, smoking status, diabetes, systolic blood 
pressure, antihypertensive medication use, low-density lipoprotein level, coronary heart 
disease, and heart failure. Age, sex, and race were self-reported. Tobacco use was defined as 
current or former cigarette smoking. Diabetes was defined as a fasting glucose level ≥126 
mg/dL (or non-fasting glucose ≥200 mg/dL), a physician diagnosis of diabetes, or use of 
diabetes medications. Systolic blood pressure was obtained from each participant using 
sphygmomanometers to measure two readings in the sitting position after 5 minutes of rest, 
with the average of the 2 measurements used as the final reading. The use of 
antihypertensive medications was self-reported. Body mass index was defined as the weight 
in kilograms divided by the square of the height in meters. Low-density lipoprotein levels 
were assayed from serum samples obtained as part of the baseline study visit. Prevalent 
heart failure was defined as present if participants reported taking heart failure medications 
or if participants met all three of the Gothenburg criteria.28 Prevalent coronary heart disease 
(CHD) was defined by a history of physician-diagnosed myocardial infarction, 
electrocardiographic Q waves, coronary artery bypass surgery, or coronary angioplasty.
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Categorical variables were reported as frequencies and percentages, and continuous 
variables as means and standard deviations. Differences between groups were tested using 
the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous 
variables. Based on prior work,11 PTFV1 values >99.9th percentile were considered extreme 
outliers and excluded from the analysis; in sensitivity analyses, these potentially outlying 
values were retained after visual inspection of these ECGs confirmed that all had abnormally 
increased PTFV1 (>4,000 μV*ms) that was not due to artifact. Kaplan-Meier estimates and 
the log-rank test were used to compare cumulative rates of stroke between participants with 
and without left atrial abnormality. Follow-up time was defined as the period from the initial 
ARIC study visit until any ischemic stroke, death, loss to follow-up, or December 31, 2010. 
Cox proportional hazards regression was used to compute hazard ratios (HR) and 95% 
confidence intervals (CI) for the association between left atrial abnormality and stroke.
Multivariable models were constructed with incremental adjustments. Model 1 adjusted for 
basic demographic characteristics (age, sex, and race). Model 2 included covariates from 
Model 1 plus body mass index, smoking status, diabetes, systolic blood pressure, 
antihypertensive medication use, low-density lipoprotein level, coronary heart disease, and 
heart failure. Model 3 included Model 2 covariates plus incident AF as a time-dependent 
covariate. Additionally, since clinically apparent AF often follows a long period of 
subclinical AF,29 Model 4 adjusted for incident AF as a time-fixed covariate (i.e., we 
assumed that incident AF was present since baseline in a subclinical form). The proportional 
hazards assumption was not violated in our analyses. We also constructed a restricted cubic 
spline model to examine the graphical dose-response relationship between PTFV1 values 
and the multivariable HR for stroke, incorporating knots at the 5th, 50th, and 95th 
percentiles. We used interaction terms to compare associations across subgroups defined by 
age (above or below the median), sex, and race (white or black).16 We defined statistical 
significance for the main effect model and interaction terms as P < 0.05. SAS version 9.3 
(Cary, NC) was used for all analyses.
Results
Of the 15,792 participants from the original ARIC cohort, 202 lacked baseline ECG data, 
110 had hemorrhagic strokes, 31 had PTFV1 values that appeared to be extreme outliers, 36 
had AF at baseline, and 871 were missing data on baseline covariates. Among the 14,542 
participants eligible for our analysis, the mean age at baseline was 54 (±5.8) years; 26% of 
the participants were black, and 55% were female. The incidence rate of AF was 7.0 (95% 
CI, 6.7-7.4) per 1,000 person-years, and during a median follow-up of 22 years (interquartile 
range, 19-23 years), 1,906 participants (13.1%) were diagnosed with AF. The 1,473 
participants (10.1%) with ECG-defined left atrial abnormality (PTFV1 >4,000 μV*ms; 
Figure 2) were generally older, more often male, more often black, and more likely to have 
vascular risk factors at baseline (Table 1).
Nine hundred and four participants (6.2%) experienced a definite or probable ischemic 
stroke (incidence rate per 1,000 person-years, 3.2; 95% CI, 3.0-3.4). A higher incidence of 
stroke occurred in those with left atrial abnormality (incidence rate per 1,000 person-years, 
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6.3; 95% CI, 5.4-7.4) than in those without (incidence rate per 1,000 person-years, 2.9; 95% 
CI, 2.7-3.1; P < 0.001; Figure 3). The risk of ischemic stroke was observed to increase 
curvilinearly with increases in PTFV1 values, as shown graphically in a restricted cubic 
spline model adjusted for baseline covariates (Figures 4 and 5).
In multivariable Cox regression models adjusted for baseline confounders as well as incident 
AF, ECG-defined left atrial abnormality was associated with incident ischemic stroke of any 
type (HR, 1.33; 95% CI, 1.11-1.59; Table 2). After excluding 474 participants with 
unknown ischemic stroke subtype or probable but not definite stroke, 430 participants had a 
definite ischemic stroke with a known subtype, of which 256 (59.6%) were non-lacunar and 
174 (40.4%) lacunar. The association between left atrial abnormality and stroke was limited 
to non-lacunar stroke (HR, 1.49; 95% CI, 1.07-2.07) as opposed to lacunar stroke (HR, 0.89; 
95% CI, 0.57-1.40; Table 2). Associations with any ischemic stroke or non-lacunar stroke 
remained similar whether or not incident AF was included in our models (Table 2). Our 
results were essentially the same in sensitivity analyses retaining all PTFV1 values instead 
of excluding values >99.9th percentile. We found no significant evidence of variation in the 
association between left atrial abnormality and stroke across subgroups defined by age, sex, 
or race (Table 3).
Discussion
We found an association between abnormally increased baseline PTFV1—an ECG marker 
of left atrial abnormality17, 30-33—and incident ischemic stroke in a large, prospective, 
population-based study. This association was limited to cases of non-lacunar (as opposed to 
lacunar) stroke, which is consistent with the hypothesis that ECG-defined left atrial 
abnormality signals a specific risk of cardiac embolism as opposed to global vascular risk. 
The relationship between left atrial abnormality and stroke did not change with adjustment 
for incident AF, suggesting that ECG-detected left atrial abnormality is associated with 
stroke independently of AF.
These results build on other recent studies that call into question whether AF—the 
dysrhythmia itself—is always a necessary step in the pathogenesis of left atrial 
thromboembolism. In a recent study of patients with pacemakers or defibrillators, 31% of 
those with both subclinical AF and stroke did not manifest atrial dysrhythmia until after 
their stroke, despite undergoing continuous heart-rhythm monitoring for a median 8 months 
before the stroke.13 Some of these strokes may have been due to causes other than cardiac 
embolism (e.g., lacunar stroke or atherosclerotic artery-to-artery embolism), but recent 
studies suggest that some resulted from atrial derangements besides the dysrhythmia that 
defines AF. Serum NT-proBNP as well as left atrial size and function on echocardiography 
have been associated with ischemic stroke independently of AF.7-10 We recently found that 
ECG-defined left atrial abnormality was associated with ischemic stroke in the Multi-Ethnic 
Study of Atherosclerosis11 and with radiographic evidence of vascular brain injury in the 
Cardiovascular Health Study;12 in both studies, these associations were essentially the same 
whether or not we adjusted for incident AF in our models, and were essentially the same in 
participants without any documented AF throughout follow-up. The present findings from 
the ARIC cohort build on these findings by indicating a specific link between atrial 
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abnormality and stroke subtypes that are not due to in-situ cerebral arterial occlusion. Cases 
of occult left atrial thromboembolism that were unrecognized because of the absence of AF 
would be expected to be classified as one of the non-lacunar stroke subtypes, not as lacunar 
stroke, which has a distinct clinical and radiographic profile. Thus, although there may be 
unmeasured confounding from atherosclerosis, our findings reduce the likelihood that the 
link between left atrial abnormality and stroke is due simply to global vascular risk factors 
such as hypertension. These results further support the hypothesis that atrial cardiopathy can 
cause stroke in the absence of AF, and that the presence of AF is not always necessary for 
embolization to occur from the left atrium.
This study has several limitations. First, participants did not undergo continuous heart-
rhythm monitoring to rule out subclinical AF, and we therefore cannot entirely exclude 
subclinical AF as a mediator in the relationship between left atrial abnormality and stroke. 
However, if AF were a significant mediator, the addition of incident AF diagnoses to our 
models should change the strength of association between left atrial abnormality and stroke, 
whereas we found essentially the same associations regardless of whether or not we included 
incident AF as a covariate. Even if undetected subclinical AF does explain some of the 
association between markers of atrial cardiopathy and stroke, as a practical matter 
measurements such as PTFV1 are easier and less costly to obtain than prolonged heart-
rhythm monitoring, suggesting that atrial markers other than AF could be found to more 
reliably diagnose the presence of atrial cardiopathy and its associated thromboembolic risk. 
Nevertheless, studies of the association between left atrial abnormality and stroke in patients 
undergoing continuous heart-rhythm monitoring would be valuable. Second, the long 
duration between baseline ECG measurements and stroke outcomes may have attenuated 
associations between left atrial abnormality and our outcomes. Third, it is possible that some 
cases classified as left atrial abnormality in our study actually involved right atrial 
abnormality. However, due to the positions of the left and right atria in relation to the 
location of the ECG electrode recording V1, left atrial abnormality typically manifests as 
increased amplitude of the terminal portion of the P-wave while right atrial abnormality 
usually manifests as increased amplitude of the early portion of the P-wave.14 This makes it 
unlikely that cases classified as left atrial abnormality in our study actually represented right 
atrial abnormality. Furthermore, misclassification of right atrial abnormality as left atrial 
abnormality should serve to attenuate any relationships between apparent left atrial 
abnormality and stroke, given that right atrial abnormality would not be expected to cause 
stroke in the majority of patients without a patent foramen ovale. Therefore, any 
misclassification would likely have biased our findings towards the null hypothesis. Fourth, 
we lacked morphological data about the left atrium, and future analyses incorporating 
additional markers of atrial dysfunction may more thoroughly delineate the relationship 
between atrial cardiopathy and stroke. Fifth, we relied on automated ECG measurements 
that are not routinely reported by current ECG systems. However, PTFV1 can be reliably 
measured manually,34, 35 and accumulating evidence regarding the association between 
ECG-defined left atrial abnormality and stroke could feasibly spur the routine reporting of 
PTFV1 on ECGs, since it is a capability that available ECG systems already possess.36
In summary, we found an association between a marker of left atrial abnormality on ECG 
and the risk of non-lacunar ischemic stroke. This association appeared independent of AF 
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diagnoses, suggesting that an underlying atrial cardiopathy can cause left atrial 
thromboembolism without necessarily manifesting with AF. Such a condition may explain 
some proportion of the 30% of ischemic strokes that currently lack a known cause.37, 38 
Given the proven benefit of anticoagulant therapy in preventing left atrial thromboembolism 
in patients with AF, future studies may be worthwhile to determine optimal markers of atrial 
cardiopathy and the effect of anticoagulant therapy in patients with conclusive evidence of 
atrial cardiopathy but no clear evidence of AF.
Acknowledgments
The authors thank the staff and participants of the ARIC study for their important contributions.
Funding/Support: This study was supported by grant K23NS082367 (Kamel) from the National Institute of 
Neurological Disorders and Stroke and the Michael Goldberg Stroke Research Fund (Kamel). The Atherosclerosis 
Risk in Communities study is carried out as a collaborative study supported by National Heart, Lung, and Blood 
Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, 
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C).
References
1. Wolf PA, Dawber TR, Thomas HE Jr. Kannel WB. Epidemiologic assessment of chronic atrial 
fibrillation and risk of stroke: the Framingham study. Neurology. 1978; 28:973–977. [PubMed: 
570666] 
2. Lackay H, Housel EL. The arrest of recurrent embolism due to auricular fibrillation with mitral 
stenosis by quinidine-anticoagulant therapy. Ann Intern Med. 1951; 35:1143–1149. [PubMed: 
14885895] 
3. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and 
nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. 
Circulation. 2002; 106:2854–2858. [PubMed: 12451014] 
4. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with 
lone atrial fibrillation. Circulation. 1997; 96:1180–1184. [PubMed: 9286947] 
5. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during 
human atrial fibrillation. Circulation. 2001; 104:174–180. [PubMed: 11447082] 
6. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial 
fibrillation. The Framingham Heart Study. Circulation. 1994; 89:724–730. [PubMed: 8313561] 
7. Benjamin EJ, D'Agostino RB, Belanger AJ, et al. Left atrial size and the risk of stroke and death. 
The Framingham Heart Study. Circulation. 1995; 92:835–841. [PubMed: 7641364] 
8. Russo C, Jin Z, Liu R, et al. LA volumes and reservoir function are associated with subclinical 
cerebrovascular disease: the CABL (Cardiovascular Abnormalities and Brain Lesions) study. JACC 
Cardiovasc Imaging. 2013; 6:313–323. [PubMed: 23473112] 
9. Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and 
incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013; 44:961–967. 
[PubMed: 23471272] 
10. Cushman M, Judd SE, Howard VJ, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: 
the reasons for geographic and racial differences in stroke cohort. Stroke. 2014; 45:1646–1650. 
[PubMed: 24757103] 
11. Kamel H, Soliman EZ, Heckbert SR, et al. P-wave morphology and the risk of incident ischemic 
stroke in the Multi-Ethnic Study of Atherosclerosis. Stroke. 2014; 45:2786–2788. [PubMed: 
25052322] 
12. Kamel H, Bartz TM, Longstreth WT Jr. et al. Association between left atrial abnormality on ECG 
and vascular brain injury on MRI in the Cardiovascular Health Study. Stroke. 2015; 46:711–716. 
[PubMed: 25677594] 
Kamel et al. Page 8













13. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial 
fibrillation and embolic events. Circulation. 2014; 129:2094–2099. [PubMed: 24633881] 
14. Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the 
standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes 
associated with cardiac chamber hypertrophy: a scientific statement from the American Heart 
Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the 
American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the 
International Society for Computerized Electrocardiology. Circulation. 2009; 119:e251–261. 
[PubMed: 19228820] 
15. Ringelstein EB, Koschorke S, Holling A, et al. Computed tomographic patterns of proven embolic 
brain infarctions. Ann Neurol. 1989; 26:759–765. [PubMed: 2604383] 
16. Soliman EZ, Prineas RJ, Case LD, et al. Ethnic distribution of ECG predictors of atrial fibrillation 
and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis 
Risk in Communities (ARIC) study. Stroke. 2009; 40:1204–1211. [PubMed: 19213946] 
17. Morris JJ Jr. Estes EH Jr. Whalen RE, et al. P-wave analysis in valvular heart disease. Circulation. 
1964; 29:242–252. [PubMed: 14119389] 
18. Jin L, Weisse AB, Hernandez F, Jordan T. Significance of electrocardiographic isolated abnormal 
terminal P-wave force (left atrial abnormality). An echocardiographic and clinical correlation. 
Arch Intern Med. 1988; 148:1545–1549. [PubMed: 2968074] 
19. Kohsaka S, Sciacca RR, Sugioka K, et al. Electrocardiographic left atrial abnormalities and risk of 
ischemic stroke. Stroke. 2005; 36:2481–2483. [PubMed: 16210557] 
20. Liu G, Tamura A, Torigoe K, et al. Abnormal P-wave terminal force in lead V1 is associated with 
cardiac death or hospitalization for heart failure in prior myocardial infarction. Heart Vessels. 
2013; 28:690–695. [PubMed: 23160859] 
21. Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation 
of the electrocardiogram: part I: The electrocardiogram and its technology: a scientific statement 
from the American Heart Association Electrocardiography and Arrhythmias Committee, Council 
on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm 
Society: endorsed by the International Society for Computerized Electrocardiology. Circulation. 
2007; 115:1306–1324. [PubMed: 17322457] 
22. Guglin ME, Thatai D. Common errors in computer electrocardiogram interpretation. Int J Cardiol. 
2006; 106:232–237. [PubMed: 16321696] 
23. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-
aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 
1999; 30:736–743. [PubMed: 10187871] 
24. Robins M, Weinfeld FD. The National Survey of Stroke. Study design and methodology. Stroke. 
1981; 12:I7–11. [PubMed: 7222169] 
25. Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-
Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009; 158:111–
117. [PubMed: 19540400] 
26. Epstein AE, Alexander JC, Gutterman DD, et al. Anticoagulation: American College of Chest 
Physicians guidelines for the prevention and management of postoperative atrial fibrillation after 
cardiac surgery. Chest. 2005; 128:24S–27S. [PubMed: 16167661] 
27. Jensen PN, Johnson K, Floyd J, et al. A systematic review of validated methods for identifying 
atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012; 21(Suppl 1):141–
147. [PubMed: 22262600] 
28. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the 
Atherosclerosis Risk in Communities study). Am J Cardiol. 2008; 101:1016–1022. [PubMed: 
18359324] 
29. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl 
J Med. 2012; 366:120–129. [PubMed: 22236222] 
30. Alpert MA, Munuswamy K. Electrocardiographic diagnosis of left atrial enlargement. Arch Intern 
Med. 1989; 149:1161–1165. [PubMed: 2524182] 
Kamel et al. Page 9













31. Goyal SB, Spodick DH. Electromechanical dysfunction of the left atrium associated with interatrial 
block. Am Heart J. 2001; 142:823–827. [PubMed: 11685169] 
32. Scott CC, Leier CV, Kilman JW, et al. The effect of left atrial histology and dimension on P wave 
morphology. J Electrocardiol. 1983; 16:363–366. [PubMed: 6227675] 
33. Weinsaft JW, Kochav JD, Kim J, et al. P wave area for quantitative electrocardiographic 
assessment of left atrial remodeling. PLoS One. 2014; 9:e99178. [PubMed: 24901435] 
34. Magnani JW, Mazzini MJ, Sullivan LM, et al. P-wave indices, distribution and quality control 
assessment (from the Framingham Heart Study). Ann Noninvasive Electrocardiol. 2010; 15:77–
84. [PubMed: 20146786] 
35. Soliman EZ, Juma H, Nkosi N. A simple electrocardiogram marker for risk stratification of 
ischemic stroke in low-resources settings. J Stroke Cerebrovasc Dis. 2010; 19:388–392. [PubMed: 
20472463] 
36. Philips 12-Lead Algorithm Physician's Guide. http://incenter.medical.philips.com/doclib/enc/fetch/
2000/4504/577242/577243/577245/577817/577818/12-
Lead_Algorithm_Physician_s_Guide_for_Algorithm_Version_PH080A%2c_(ENG).pdf
%3fnodeid%3d3325283%26vernum%3d1. Accessed April 20, 2015
37. Marnane M, Duggan CA, Sheehan OC, et al. Stroke subtype classification to mechanism-specific 
and undetermined categories by TOAST, A-S-C-O, and Causative Classification system. Stroke. 
2010; 41:1579–1586. [PubMed: 20595675] 
38. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new 
clinical construct. Lancet Neurol. 2014; 13:429–438. [PubMed: 24646875] 
Kamel et al. Page 10














Schematic Illustration and Examples of Normal and Abnormal P-Wave Terminal Force in 
Electrocardiogram Lead V1 (PTFV1).
PTFV1 was defined as the absolute value of the amplitude (P’amp) multiplied by the duration 
(P’dur) of the terminal portion of the P-wave (P’; shaded area) in lead V1 of a standard 12-
lead electrocardiogram (Panel A). Panel B shows an example of a P-wave with normal 
PTFV1 (dashed arrow), while Panel C shows an example of a P-wave with abnormally 
increased PTFV1 (solid arrow). Note the wider and deeper downward deflection of the P-
wave in Panel C compared with Panel B.
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Distribution of Baseline Values of P-Wave Terminal Force in Electrocardiogram Lead V1 
(PTFV1).
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Cumulative Incidence of Ischemic Stroke, Stratified by Baseline Left Atrial Abnormality.
Left atrial abnormality was defined as P-wave terminal force in electrocardiogram lead V1 
>4,000 μV*ms. The dashed line represents study participants with left atrial abnormality, 
and the solid line those without left atrial abnormality. The difference in cumulative rates 
between groups was significant by the log-rank test (P < 0.001).
Kamel et al. Page 13














Relationship Between P-Wave Terminal Force in Electrocardiogram Lead V1 (PTFV1) and 
the Risk of Incident Ischemic Stroke.
The plot displays the results of a restricted cubic spline model (see text for details). The 
dotted horizontal lines represent the 95% confidence interval, and the dotted vertical line 
represents the threshold of 4,000 μV*ms that was used to define left atrial abnormality.
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Relationship Between P-Wave Terminal Force in Electrocardiogram Lead V1 (PTFV1) and 
the Risk of Incident Non-Lacunar Stroke.
The plot displays the results of a restricted cubic spline model (see text for details). The 
dotted horizontal lines represent the 95% confidence interval, and the dotted vertical line 
represents the threshold of 4,000 μV*ms that was used to define left atrial abnormality.
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Table 1
Baseline Characteristics of ARIC Study Participants, Stratified by Abnormally Increased P-Wave Terminal 









(N = 13,069) P value
c
Age, mean (SD), years 56 (5.5) 54 (5.7) <0.001
Male 763 (51.8) 5,747 (44.0) <0.001
White 889 (60.4) 9,846 (75.3) <0.001
Tobacco use 955 (64.8) 7,542 (57.7) <0.001
Diabetes 286 (19.4) 1,348 (10.3) <0.001
Low-density lipoprotein, mean (SD), mg/dl 141 (42.0) 137 (39.0) <0.001
Body mass index, mean (SD) mg/kg2 29 (5.7) 28 (5.3) <0.001
Systolic blood pressure, mean (SD), mm Hg 129 (23.0) 120 (18.0) <0.001
Antihypertensive medication use 701 (47.6) 3,646 (27.9) <0.001
Coronary heart disease 158 (10.7) 528 (4.0) <0.001
Heart failure 135 (9.2) 519 (4.0) <0.001
Abbreviations: ARIC, Atherosclerosis Risk in Communities; ECG, electrocardiogram; PTFV1, P-wave terminal force in lead V1; SD, 
standard deviation.
a
Data are presented as number (%) unless otherwise specified.
b
PTFV1 was defined as the absolute value of the amplitude of the terminal portion of the P-wave in ECG lead V1 multiplied by its 
duration. Abnormal PTFV1 was defined as >4,000 μV*ms.
c
Differences between groups were compared using the chi-square test for categorical variables and the Wilcoxon-rank sum test for 
continuous variables.
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Table 2












Any ischemic strokef 1.69 (1.42-2.01) 1.31 (1.10-1.57) 1.33 (1.11-1.59) 1.29 (1.08-1.54)
Ischemic stroke
subtypesg
 Non-lacunar stroke 1.83 (1.33-2.52) 1.44 (1.04-1.99) 1.49 (1.07-2.07) 1.44 (1.04-1.99)
 Lacunar stroke 1.22 (0.79-1.89) 0.88 (0.57-1.38) 0.89 (0.57-1.40) 0.91 (0.58-1.42)
a
Results are reported as the hazard ratio (95% confidence interval) for values of PTFV1 >4,000 μV*ms compared to ≤4,000 μV*ms. 
PTFV1 was defined as the absolute value of the amplitude of the terminal portion of the P-wave in ECG lead V1 multiplied by its 
duration.
b
Adjusted for baseline age, sex, and race.
c
Adjusted for Model 1 covariates plus baseline body mass index, smoking status, diabetes, systolic blood pressure, antihypertensive 
medication use, low-density lipoprotein level, coronary heart disease, and heart failure.
d
Adjusted for Model 2 covariates plus atrial fibrillation as a time-dependent covariate.
e
Adjusted for Model 2 covariates plus atrial fibrillation as a time-fixed covariate.
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Table 3
Associations between Abnormally Increased P-Wave Terminal Force in ECG Lead V1 (PTFV1) and Incident 
















 <54 y 2.03 (1.46-2.84) 1.29 (0.91-1.81) 1.29 (0.91-1.82) 1.23 (0.87-1.74)
 ≥54 y 1.68 (1.37-2.05) 1.35 (1.10-1.66) 1.38 (1.12-1.70) 1.32 (1.08-1.63)
Sex 0.36
 Male 1.87 (1.48-2.35) 1.46 (1.15-1.85) 1.50 (1.19-1.91) 1.44 (1.13-1.82)
 Female 1.50 (1.14-1.96) 1.19 (0.91-1.56) 1.19 (0.91-1.57) 1.18 (0.90-1.55)
Race 0.84
 White 1.56 (1.22-1.99) 1.25 (0.97-1.61) 1.29 (1.00-1.66) 1.17 (0.91-1.51)
 Black 1.85 (1.45-2.37) 1.38 (1.07-1.78) 1.38 (1.07-1.77) 1.42 (1.10-1.83)
a
Results are reported as the hazard ratio (95% confidence interval) for values of PTFV1 >4,000 μV*ms compared to ≤4,000 μV*ms.
b
Adjusted for age, sex, and race.
c
Adjusted for Model 1 covariates plus baseline body mass index, smoking status, diabetes, systolic blood pressure, antihypertensive 
medication use, low-density lipoprotein level, coronary heart disease, and heart failure.
d
Adjusted for Model 2 covariates plus atrial fibrillation as a time-dependent covariate.
e
Adjusted for Model 2 covariates plus atrial fibrillation as a time-fixed covariate.
f
Interactions tested using Model 2.
g
Dichotomized at the median age for study participants.
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